FDA
Potassium Phosphates
The FDA lists this product in 19 strengths and forms.
Indications
Potassium Phosphates in Sodium Chloride Injection is indicated as a source of phosphorus to correct hypophosphatemia in adults and pediatric patients who weigh 40 kg or greater when oral or enteral replacement is not possible, insufficient, or contraindicated. Potassium Phosphates in Sodium Chloride Injection is a phosphorus replacement product indicated as a source of phosphorus to correct hypophosphatemia in adults and pediatric patients who weigh 40 kg or greater when oral or enteral replacement is not possible, insufficient, or contraindicated.
( 1 )
Contraindications
Potassium Phosphates in Sodium Chloride Injection is contraindicated in patients with:
- hyperkalemia [see Warning and Precautions ( 5.2 )]
- hyperphosphatemia [see Warning and Precautions ( 5.4 )]
- hypercalcemia or significant hypocalcemia [see Warning and Precautions ( 5.4 )]
- severe renal impairment (eGFR less than 30 mL/min/1.73m 2 ) [see Warning and Precautions ( 5.2 )]
- hyperkalemia ( 4 )
- hyperphosphatemia ( 4 )
- hypercalcemia or significant hypocalcemia ( 4 )
- severe renal impairment (eGFR less than 30 mL/min/1.73m 2 ) ( 4 )
Warnings and precautions
- Serious Cardiac Adverse Reactions with Bolus, or Rapid Intravenous Administration : Do not exceed the recommended infusion rate. Continuous electrocardiographic (ECG) monitoring may be needed during infusion. ( 2.3 , 5.1 )
- Hyperkalemia : Increased risk in patients with renal impairment, severe adrenal insufficiency, or treated with drugs that increase potassium. Patients with cardiac disease may be more susceptible. Do not exceed the maximum daily amount of potassium or the recommended infusion rate. Continuous ECG monitoring may be needed during infusion. ( 5.2 , 7.1 )
- Pulmonary Embolism due to Pulmonary Vascular Precipitates : If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation. ( 5.3 )